Lisata closes Marea reverse merger; $225M PIPE financing

LISATA THERAPEUTICS, INC.

Merger closed Sept 17, 2026; Marea stockholders get 1,793,129 LSTA shares + 211,365 Series C preferred (convertible to common).
$225M PIPE: 150,867.995 Series C preferred shares sold to investors; expected close Sept 18, 2026.
Post-deal ownership: LSTA legacy holders ~2.39%, Marea holders ~59.54%, PIPE investors ~38.07% (on conversion).
Ted Love (ex-GBT CEO) joins board; Josh Lehrer (Marea CEO) named President & COO; Mazzo stays CEO.
180-day lock-up on insider shares; stockholder vote needed for Series C conversion and change of control.

item 1.01 item 5.03 item 2.01 item 3.02 item 5.02 item 7.01 item 9.01

Featured in Daily 8-K Digest

Selected #1 for 2026-09-17. Read digest

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

David J. Mazzo

President

LSTA · LISATA THERAPEUTICS, INC.

Effective: 2026-09-17
Successor: Josh Lehrer
Filed: September 17, 2026, 9:27 AM ET

Immediately prior to such appointment, David J. Mazzo, Ph.D. resigned solely from the office of President, but he retained his position as Chief Executive Officer of the Company.

Appointed

Josh Lehrer

President and Chief Operating Officer

LSTA · LISATA THERAPEUTICS, INC.

Effective: 2026-09-17
Filed: September 17, 2026, 9:27 AM ET

In accordance with the Merger Agreement, on September 17, 2026 , effective immediately after the First Effective Time, Josh Lehrer, M.D., M.Phil., FACC was appointed as the President and Chief Operating Officer of the Company.

Appointed

Ted W. Love

Director

LSTA · LISATA THERAPEUTICS, INC.

Effective: 2026-09-17
Filed: September 17, 2026, 9:27 AM ET

In accordance with the Merger Agreement, on September 17, 2026 , effective immediately after the First Effective Time, Ted W. Love, M.D. was appointed to the Board as a director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David J. Mazzo resigned as President at LISATA THERAPEUTICS, INC..

Action: resigned
Role: President

Exact text from the filing

Immediately prior to such appointment, David J. Mazzo, Ph.D. resigned solely from the office of President, but he retained his position as Chief Executive Officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Josh Lehrer was appointed as President and Chief Operating Officer at LISATA THERAPEUTICS, INC..

Action: appointed
Role: President and Chief Operating Officer

Exact text from the filing

In accordance with the Merger Agreement, on September 17, 2026 , effective immediately after the First Effective Time, Josh Lehrer, M.D., M.Phil., FACC was appointed as the President and Chief Operating Officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Ted W. Love was appointed as Director at LISATA THERAPEUTICS, INC..

Action: appointed
Role: Director

Exact text from the filing

In accordance with the Merger Agreement, on September 17, 2026 , effective immediately after the First Effective Time, Ted W. Love, M.D. was appointed to the Board as a director.

View on SEC.gov

LISATA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-26-036866

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.